FDA approval, fundraising, and the reality of building in healthcare according to BioticsAI founder

In the healthcare industry, speed isn't always the best strategy. Founders like Robhy Bustami, the co-founder and CEO of BioticsAI, understand that building successful solutions requires a methodical approach. His company is focused on developing an AI copilot for ultrasound technology aimed at identifying fetal abnormalities, an area plagued by significant misdiagnosis rates. In a recent conversation with Isabelle Johannessen on Build Mode, Bustami shared the challenges his team faced in a heavily regulated environment. BioticsAI's journey started with limited resources, crafting an initial product prototype for under $100,000—a remarkable achievement in the medical device sector. This early success helped them secure a victory at the TechCrunch Startup Battlefield in 2023, enhancing their visibility and credibility. The company achieved a significant milestone in January when they received FDA approval, allowing them to begin deploying their technology in hospitals and scaling their operations. From the outset, BioticsAI has integrated FDA approval into their product development strategy, emphasizing clinical validation and regulatory considerations throughout the process. This proactive approach involved collaborating closely with healthcare professionals, gathering extensive datasets, and conducting structured clinical studies before even submitting their product for review. Bustami highlighted that the FDA approval process, often considered opaque, can be navigated with early engagement. By participating in pre-submission meetings, the team was able to clarify study designs and align expectations. However, the journey is not without its risks. Investors typically express concerns about the potential for FDA rejection, which underscores the importance of maintaining team motivation during lengthy timelines. At BioticsAI, fostering a culture of alignment across engineers, clinicians, and researchers has been crucial. Bustami stressed the importance of celebrating small victories in research and development, which helps sustain morale even when significant milestones are far off. Now that FDA clearance has been achieved, BioticsAI is poised for a new chapter, beginning the rollout of its technology in hospitals and planning to expand its focus from obstetrics to other areas of reproductive health. Building in the healthcare sector is undoubtedly a long and challenging endeavor, but for those willing to commit, the potential to transform patient care is a powerful motivator.